Mineralys Therapeutics, Inc. MLYS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$151.78M+1.9% | -$154.65M+9.8% | -$171.36M+10.2% | -$190.77M-1.2% | -$188.51M-6.0% | ||
| $50K-15.3% | $59K-3.3% | $61K+7.0% | $57K+14.0% | $50K+16.3% | ||
| $22.23M+15.0% | $19.32M+12.5% | $17.17M+18.7% | $14.47M+13.1% | $12.79M+12.8% | ||
| -$136.4M+4.2% | -$142.42M+16.9% | -$171.37M+11.1% | -$192.69M0.0% | -$192.66M-15.8% | ||
| -$341.82M+12.3% | -$389.75M-92.3% | -$202.69M-839% | $27.42M-64.9% | $78.04M-32.1% | ||
| $425.99M-27.9% | $591M+19.5% | $494.39M— | —— | —— | ||
| —— | —— | $120.32M+255% | $33.93M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Mineralys Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.